Effects of Gefitinib targeted therapy in elderly patients with advanced non-small cell lung cancer
Objective:To observe effects of Gefitinib targeted therapy on elderly patients with advanced non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 95 elderly patients with advanced NSCLC admitted to the hospital from October 2020 to October 2022.According to the random number table method,they were divided into study group(n=48)and control group(n=47).The control group was treated with conventional DP regimen(Docetaxel+Cisplatin)chemotherapy,while the study group was treated with Gefitinib tablets for targeted therapy.The clinical efficacy,the serum tumor markers[carcinoembryonic antigen(CEA),thymidine kinase 1(TK1),cytokeratin 19 fragment(CYFRA21-1)]and cell migration indexes[matrix metalloproteinase-9(MMP-9),matrix metalloproteinase inhibitor-1(TIMP-1)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the study group was 75.00%(36/48),which was higher than 48.94%(23/47)of the control group,and the difference was statistically significant(P＜0.05).After 3 weeks of treatment,the levels of serum CYFRA21-1,CEA,TK1,TIMP-1 and MMP-9 in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Further,the incidence of adverse reactions in the study group was 39.58%(19/48),which was lower than 85.11%(40/47)in the control group,and the difference was statistically significant(P＜0.05).Conclusions:Gefitinib targeted therapy for the elderly patients with advanced NSCLC can improve the clinical efficacy,reduce the levels of serum tumor markers as well as cell migration indexes,and has high safety.Moreover,it is superior to conventional chemotherapy.
NETL
NSTL
万方数据
